PODD · Insulet Corporation
$131.96
-2.02% last session
End-of-day data · close of 2026-09-11
Market cap
$9B
Enterprise value
$10B
Trailing P/E
25.3
Forward P/E
17.5
Dividend yield
—
Beta
1.08
Avg volume
2M
Employees
5K
Daily Change %
-2.02%
5 Days Change
-6.48%
10 Days Change
-7.22%
30 Days Change
-4.69%
60 Days Change
-14.48%
Month to Day Change
-7.05%
Year to Day Change
-51.48%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — PODD
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-08-06
Latest call per bank · past 12 months
UBS
Neutral$150
+11.4% vs priceRBC Capital
Outperform$160
+18.8% vs priceWells Fargo
Equal-Weight$144
+6.9% vs priceJP Morgan
Neutral$152
+12.9% vs priceCitigroup
Neutral$172
+27.7% vs priceDeutsche Bank
Buy$190
+41.1% vs priceBank of America
Buy$208
+54.4% vs priceBarclays
Underweight$198
+47.0% vs priceGoldman Sachs
Buy$277
+105.7% vs priceJefferies
Buy$400
+197.0% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-06 | Canaccord Genuity | Maintains | Buy | $249 → $179 |
| 2026-08-06 | Leerink Partners | Downgrade | Outperform → Market Perform | $247 → $145 |
| 2026-08-06 | TD Cowen | Maintains | Hold | $294 → $144 |
| 2026-08-06 | UBS | Maintains | Neutral | $174 → $150 |
| 2026-08-06 | RBC Capital | Maintains | Outperform | $245 → $160 |
| 2026-08-06 | Bernstein | Maintains | Outperform | $200 → $175 |
| 2026-08-06 | Benchmark | Maintains | Buy | $250 → $185 |
| 2026-08-06 | Stifel | Maintains | Buy | $225 → $180 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 33 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 13.6% below the 50-day MA ($152.70).
- Price vs 200-day MA: Trading 36.0% below the 200-day MA ($206.32).
- MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- MACD (12,26,9): MACD histogram is negative (-1.04) — short-term momentum is fading.
- 52-week range: Price is within 10% of the 52-week low ($131.96).
PODD Price Chart
Loading chart for PODD…
Fundamentals
About Insulet Corporation
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
More in Medical Devices
ABT
Abbott Laboratories
$179B -14.4% YTD
MDT
Medtronic plc.
$117B -2.7% YTD
SYK
Stryker Corporation
$104B -21.2% YTD
BSX
Boston Scientific Corporation
$62B -52.8% YTD
EW
Edwards Lifesciences Corporatio
$50B 1.1% YTD
DXCM
DexCom, Inc.
$32B 26.4% YTD
GEHC
GE HealthCare Technologies Inc.
$29B -20.4% YTD
PHG
Koninklijke Philips N.V. NY Reg
$24B -4.0% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.